Capricor Therapeutics (NASDAQ: CAPR) reports sustained efficacy and safety in 4-year DMD trial of Deramiocel

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on cell and exosome-based therapies for rare diseases, announced on June 20, 2025, that long-term data from its HOPE-2 Open-Label Extension (OLE) study of Deramiocel showed sustained clinical benefit across cardiac and skeletal muscle outcomes in patients with Duchenne Muscular Dystrophy (DMD). The four-year dataset, presented at the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference in Las Vegas, demonstrated minimal cardiac function decline and a slowed progression of upper limb deterioration, with a consistent safety profile across the treatment period.

The trial’s findings arrive at a critical moment as Deramiocel remains under priority review by the U.S. Food and Drug Administration (FDA) following the company’s Biologics License Application (BLA). Capricor Therapeutics has emphasized that there have been no delays in its regulatory communications to date, and the four-year data bolster its case for potential approval in the United States and Japan.

How does the four-year HOPE-2 study data support Deramiocel’s long-term role in managing Duchenne muscular dystrophy?

The new data from the HOPE-2 OLE study indicate a median change of only -0.5 points from baseline in cardiac function after four years of continuous treatment with Deramiocel. In a subgroup of patients who began the study with a left ventricular ejection fraction (LVEF) above 45%, outcomes were even more favorable, suggesting the therapy may be most effective when administered earlier in disease progression.

In terms of skeletal muscle health, the trajectory of disease progression continued to decelerate with time. Patients in their fourth year of Deramiocel treatment showed a smaller average decline of 0.6 points on the Performance of the Upper Limb scale (PUL v2.0), compared to a 1.8-point decline in the first year. These results suggest the therapy may not only stabilize but gradually attenuate DMD’s degenerative course with sustained use.

Throughout the trial, Deramiocel maintained a strong safety profile with no new adverse safety trends observed. This consistent tolerability, combined with multi-system efficacy, distinguishes Deramiocel from other investigational therapies that primarily target either skeletal or cardiac dysfunction in isolation.

What are analysts and institutional investors watching in Capricor’s clinical and regulatory progress?

Institutional investors are closely tracking Capricor Therapeutics’ path toward regulatory approval, especially given the company’s exclusive U.S. and Japan commercialization agreement with Nippon Shinyaku Co., Ltd. and its U.S. affiliate NS Pharma, Inc. This partnership is expected to enable rapid commercialization upon approval and has positioned Capricor as a potentially pivotal player in the underserved DMD treatment space.

While Capricor has not disclosed detailed financial terms of the deal, institutional sentiment suggests that the agreement could unlock milestone-based payments and royalty streams that improve the biotech firm’s revenue outlook significantly upon a successful FDA review. Capricor’s stock (NASDAQ: CAPR) has responded positively in previous quarters to clinical updates and regulatory progress, although volatility remains typical for companies in late-stage drug development.

How does Deramiocel compare with other emerging treatment approaches in Duchenne muscular dystrophy?

Unlike gene therapies or antisense oligonucleotides that aim to restore dystrophin expression, Deramiocel (formerly known as CAP-1002) is an allogeneic cell therapy based on cardiosphere-derived cells (CDCs). These CDCs secrete bioactive exosomes that reprogram immune responses, reduce fibrosis, and support regeneration in both skeletal and cardiac muscle.

This immunomodulatory approach provides a differentiated mechanism that does not rely on genetic correction, allowing broader applicability across DMD patients regardless of genotype. CDCs have been evaluated in over 250 peer-reviewed scientific studies and used in more than 250 human subjects across multiple clinical trials. Preclinical evidence also supports Deramiocel’s dual-action effects in dystrophinopathies, including Duchenne and Becker variants.

Deramiocel has been awarded multiple designations to expedite its development, including Orphan Drug Designation in both the U.S. and Europe, Regenerative Medicine Advanced Therapy (RMAT) designation in the United States, and Advanced Therapy Medicinal Product (ATMP) designation in Europe. It also holds Rare Pediatric Disease Designation from the FDA, which could qualify Capricor for a Priority Review Voucher if the therapy gains approval.

What are the clinical and regulatory milestones ahead for Deramiocel in 2025 and beyond?

Following the successful BLA submission and continued FDA review, Capricor anticipates further regulatory updates in the second half of 2025. If approved, Deramiocel would represent one of the first cell therapies to offer long-term organ protection in DMD, targeting both skeletal muscle deterioration and cardiomyopathy—two of the disease’s most devastating manifestations.

The ongoing HOPE-2 OLE study continues to monitor patient safety, cardiac health, and upper limb function, providing an expanding dataset that may support future label expansions or post-marketing surveillance requirements. Meanwhile, Capricor’s broader research platform is advancing other programs based on its proprietary StealthX exosome technology, with preclinical studies underway in vaccinology and targeted molecular delivery.

Capricor’s Chief Executive Officer, Dr. Linda Marbán, noted that the firm is “executing with urgency” and maintaining steady communication with regulators. She acknowledged the contributions of patients, families, and clinicians who have participated in the multi-year program.

Why is multi-organ therapeutic targeting crucial in managing Duchenne muscular dystrophy today?

Duchenne Muscular Dystrophy is a rare, X-linked genetic disorder caused by the absence of dystrophin, a structural protein necessary for muscle cell integrity. Affecting approximately 15,000 people in the United States, DMD primarily strikes boys in early childhood and results in progressive loss of mobility, respiratory decline, and eventually heart failure. There is currently no cure, and available treatments are limited in scope and duration of effect.

As heart failure has emerged as the leading cause of death in DMD, therapies that can stabilize or slow cardiac decline are increasingly viewed as essential to long-term disease management. The ability of Deramiocel to preserve both cardiac and skeletal muscle function over four years positions it as a potential cornerstone in multi-organ disease management strategies.

Patient advocacy groups such as PPMD have emphasized the importance of developing treatments that extend quality of life and delay disease milestones. PPMD President Pat Furlong characterized the new data as “encouraging,” particularly in light of the cardiac stabilization observed in long-term recipients of Deramiocel.

What strategic opportunities does Capricor’s exosome platform present beyond Duchenne therapy?

While Deramiocel remains Capricor Therapeutics’ flagship asset, the American biotech company is also leveraging its StealthX exosome platform in other therapeutic areas. The platform is under preclinical investigation for delivering small molecules, proteins, and oligonucleotides with high precision, particularly in conditions where systemic delivery has proven ineffective or unsafe.

This exosome-driven strategy could potentially expand Capricor’s future pipeline into areas such as cancer, inflammation, infectious disease, and rare genetic disorders—although no investigational candidates beyond Deramiocel are yet in clinical-stage development.